NuVasive will sponsor and participate in EUROSPINE 2022

SAN DIEGO, October 17, 2022 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the spine technology innovation leader focused on transforming spine surgery with minimally disruptive and procedurally integrated solutions, has announced today that it will continue its partnership with EUROSPINE as Gold Sponsor and attend EUROSPINE 2022 October 19 to 21 in Milano.

“Our support for EUROSPINE reflects our belief in partnering with the most influential societies, study groups and congresses around the world to improve spine care and change the lives of more patients,” said Chris Barry, CEO of NuVasive. “With our set of industry-leading procedural solutions, enabled by Pulse technologies, we continue to build the future of spine care to deliver smarter surgery.”

NuVasive will organize a lunch-workshop, Impulse®: When precision meets innovation, on Wednesday, October 19 from 11:45 a.m. to 1:45 p.m. CEST in the Brown 2 room of the Milano Convention Center. Mr. Morgan JonesRoyal Orthopedic Hospital, National Health Service Trust and Birmingham Children’s Hospital, and Dr. Sven Vetter, BG Klinik Ludwigshafen, will demonstrate how Pulse has impacted their operating rooms (OR) with its navigational precision. Surgeons will also have the opportunity to demo Pulse and Cios Spin from Siemens Healthineers at the NuVasive booth, seeing first-hand how the two support a more efficient navigational workflow in the operating room. .

NuVasive Booth #98 will feature several Meet the expert sessions:

  • Impulse: Expert Review of Its Modalities—Join Dr. Sven Vetter on Wednesday October 19as it introduces Pulse, an enabling technology platform that integrates intraoperative neuromonitoring, global alignment, rod bending, radiation reduction and imaging enhancement, and navigation.
  • Relining® 3D: An expert’s guide to correcting 3D distortion—Join Mr. Stewart TuckerGreat Ormond Street Hospital, the Thursday October 20while it introduces Reline 3D, a posterior fixation system optimized to address three-dimensional deformities found in the spine.
  • X360: The Journey of a Single Position Surgery (SPS) Expert—Join Prof. dr. Dominique A. RothenfluhLausanne University Hospitals, the friday 21 octoberas it introduces X360, a full lateral approach to SPS that leverages advanced techniques and technologies to help surgeons deliver patient-specific surgical plans while improving workflow and operating room efficiency .

For more information, please visit the NuVasive EUROSPINE webpage here.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care and change lives. The company’s less invasive and procedurally integrated surgical solutions are designed to provide reproducible, clinically proven results. The company’s comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, surgical planning software, navigation and imaging solutions, adjustable implant systems magnetic spine and orthopedics, as well as intraoperative neuromonitoring technologies and services. With over $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-looking statements

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if not materialized or prove to be incorrect, could cause NuVasive results to differ. materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that contribute to the uncertain nature of these statements include, among others, the risks associated with the acceptance of the Company’s surgical products and procedures by spine surgeons and hospitals, the development and acceptance of new products or product improvements, clinical and statistical verification of the benefits obtained from the use of NuVasive’s products, the Company’s ability to adequately manage inventory as it continues to introduce new products, its ability to recruit and retain management and key personnel; and other risks and uncertainties described in NuVasive’s press releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive undertakes no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date on which it was made.

SOURCENuVasive, Inc.


#NuVasive #sponsor #participate #EUROSPINE

Related Articles

Back to top button